EP1133689A4 - DIAGNOSIS OF NEOPLASIA - Google Patents

DIAGNOSIS OF NEOPLASIA

Info

Publication number
EP1133689A4
EP1133689A4 EP99961832A EP99961832A EP1133689A4 EP 1133689 A4 EP1133689 A4 EP 1133689A4 EP 99961832 A EP99961832 A EP 99961832A EP 99961832 A EP99961832 A EP 99961832A EP 1133689 A4 EP1133689 A4 EP 1133689A4
Authority
EP
European Patent Office
Prior art keywords
diagnosing neoplasia
neoplasia
diagnosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99961832A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1133689A1 (en
Inventor
Li Liu
Bing Zhu
Han Li
W Joseph Thompson
Gary A Piazza
Rifat Pamukcu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
Cell Pathways Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Pathways Inc filed Critical Cell Pathways Inc
Publication of EP1133689A1 publication Critical patent/EP1133689A1/en
Publication of EP1133689A4 publication Critical patent/EP1133689A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP99961832A 1998-11-25 1999-11-24 DIAGNOSIS OF NEOPLASIA Withdrawn EP1133689A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20002598A 1998-11-25 1998-11-25
US20066298A 1998-11-25 1998-11-25
US200025 1998-11-25
US200662 1998-11-25
PCT/US1999/028099 WO2000033067A1 (en) 1998-11-25 1999-11-24 Method for diagnosing neoplasia

Publications (2)

Publication Number Publication Date
EP1133689A1 EP1133689A1 (en) 2001-09-19
EP1133689A4 true EP1133689A4 (en) 2002-10-30

Family

ID=26895400

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99961832A Withdrawn EP1133689A4 (en) 1998-11-25 1999-11-24 DIAGNOSIS OF NEOPLASIA

Country Status (4)

Country Link
EP (1) EP1133689A4 (enExample)
JP (1) JP2002531826A (enExample)
AU (1) AU1833000A (enExample)
WO (1) WO2000033067A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794192B2 (en) 2000-06-29 2004-09-21 Pfizer Inc. Target
GB0016009D0 (en) * 2000-06-29 2000-08-23 Pfizer Ltd Target

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0997145A1 (en) * 1998-10-15 2000-05-03 Cell Pathways, Inc. Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401774A (en) * 1991-03-08 1995-03-28 University Of Arizona Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
DE69202721T2 (de) * 1991-03-08 1995-10-12 Fgn Inc Substituierte Indenylverbindungen.
ES2156898T3 (es) * 1993-05-27 2001-08-01 Univ Washington Materiales de fosfodiesterasa especifica de gmp ciclico que se une a gmp ciclico y procedimientos para su preparacion.
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0997145A1 (en) * 1998-10-15 2000-05-03 Cell Pathways, Inc. Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds
EP1161943A2 (en) * 1998-10-15 2001-12-12 Cell Pathways, Inc. Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRANCIS SHARRON H ET AL: "Ligand-induced conformational changes in cyclic nucleotide phosphodiesterases and cyclic nucleotide-dependent protein kinase.", METHODS (ORLANDO), vol. 14, no. 1, January 1998 (1998-01-01), pages 81 - 92, XP002206143, ISSN: 1046-2023 *
See also references of WO0033067A1 *
YANAKA NORIYUKI ET AL: "Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene.", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 255, no. 2, 2 July 1998 (1998-07-02), pages 391 - 399, XP002195923, ISSN: 0014-2956 *

Also Published As

Publication number Publication date
JP2002531826A (ja) 2002-09-24
WO2000033067A1 (en) 2000-06-08
AU1833000A (en) 2000-06-19
EP1133689A1 (en) 2001-09-19

Similar Documents

Publication Publication Date Title
GB9810722D0 (en) Method
GB9809414D0 (en) Method
GB9607287D0 (en) Diagnosis method
GB9820919D0 (en) Diagnostic method
GB9809776D0 (en) Method
GB2345341B (en) Engine diagnostic method
GB9814055D0 (en) Method
EP1133689A4 (en) DIAGNOSIS OF NEOPLASIA
GB9929720D0 (en) Diagnostic method
GB9802475D0 (en) Method
GB9817266D0 (en) Method
AUPP612798A0 (en) Diagnostic method
AU1984900A (en) Diagnostic method
GB9809780D0 (en) Method
GB9809782D0 (en) Method
GB9818592D0 (en) Diagnosis method
GB9818319D0 (en) Fungicidal test method
GB9825374D0 (en) Method
GB9813126D0 (en) Method
GB9804355D0 (en) Method
GB9807772D0 (en) Test method
AUPO786097A0 (en) Method for diagnosing malignancy
GB9722850D0 (en) Diagnostic method
GB9926293D0 (en) Diagnostic method
GB9924534D0 (en) Diagnostic Method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010523

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PAMUKCU, RIFAT

Inventor name: PIAZZA, GARY, A.

Inventor name: THOMPSON, W., JOSEPH

Inventor name: LI, HAN

Inventor name: ZHU, BING

Inventor name: LIU, LI

A4 Supplementary search report drawn up and despatched

Effective date: 20020911

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OSI PHARMACEUTICALS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OSI PHARMACEUTICALS, INC.

17Q First examination report despatched

Effective date: 20060505

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110208